2 Result: Pharvaris
Pharvaris Gains Momentum, Avalo Therapeutics and FibroGen Suffer Setbacks
June 26th, 2023
Shares of Pharvaris N.V. (Nasdaq: PHVS) surged over 10% in pre-market trading after the clinical-stage company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application f. Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
September 04th, 2026Signing Day Is Not the End of Recruiting
September 04th, 2026Treasury, IRS Move to End Tax-Exempt Status for Discriminatory Practices in Private Schools
September 03rd, 2026FDA Approves First Drug to Treat Alexander Disease
September 03rd, 2026How Coaching Staffs Evaluate Athletes Across a Season
September 03rd, 2026
Member Login